Report of Canonical BCR- ABL1 Fusion in Glioblastoma

JCO Precis Oncol. 2021 Aug 25:5:PO.20.00519. doi: 10.1200/PO.20.00519. eCollection 2021.

Authors

Ying Pang¹, Guangyang Yu¹, Madison Butler¹, Sivasish Sindiri², Young K Song², Jun S Wei², Xinyu Wen², Hisen-Chao Chou², Martha Quezado³, Svetlana Pack³, Liqiang Xi³, Zied Abdullaev³, Olga Kim¹, Alice Ranjan¹, Mythili Merchant¹, Ramya Antony¹, Lisa Boris¹, Orwa Aboud^{1

4}, David Kamson^{1

4}, Rosandra Kaplan⁵, Megan Mackey⁶, Kevin Camphausen⁶, Kareem Zaghloul⁷, Terri S Armstrong¹, Mark R Gilbert¹, Kenneth Aldape³, Matthias Holdhoff⁸, Javed Khan², Jing Wu¹

Affiliations

¹ Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
² Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
³ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
⁴ Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
⁶ Radiation Oncology Branch, National Cancer Institute, Bethesda, MD.
⁷ Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD.
⁸ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD.

No abstract available

Publication types

Case Reports
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Female
Fusion Proteins, bcr-abl / genetics*
Glioblastoma / diagnosis
Glioblastoma / drug therapy*
Glioblastoma / genetics*
Glioblastoma / surgery
Humans
Imatinib Mesylate / therapeutic use
Magnetic Resonance Imaging
Middle Aged
Protein Kinase Inhibitors / therapeutic use*

Substances

BCR-ABL1 fusion protein, human
Protein Kinase Inhibitors
Imatinib Mesylate
Fusion Proteins, bcr-abl